First therapy for children with debilitating NF-1 approved in the USA

April 12, 2020 – The human genetic disease neurofibromatosis type 1 (NF-1) is a complex multi-system disorder caused by the mutation of a gene  (NF1 gene) on chromosome 17 that is responsible for production of a protein called neurofibromin which is needed for normal function in many human cell types. NF-1 causes tumors along the nervous system which can grow anywhere on the body. NF-1 is one of the most common genetic disorders and is not limited to any person’s race or sex. NF-1 is an autosomal dominant disorder which means that mutation or deletion of one copy (or allele) of the NF-1 gene is sufficient for the development of NF-1, although presentation varies widely.

Neurofibromatosis type I (NF-1)

In the midst of its occupany with the rise of Covid-19, the American Food and Drug Administration (FDA) just approved Selumetinib (Koselugo) for the treatment of pediatric patients, 2 years of age and older, who suffer from debilitating, progressive, and often disfiguring yet rare neurofibromatosis type 1 (NF-1), which typically begins early in life. In fact, NF-1 is an age specific disease; most signs of NF-1 are visible after birth (during infancy), but many symptoms of NF-1 occur as the person ages and changes hormonal status. NF-1 is usually diagnosed in early childhood and appears in an estimated 1 out of every 3,000 infants. As of 2015, there were at least 100,000 people in the U.S. and about 15,000 people in the UK who had been diagnosed with NF. Common symptoms of NF-1 include brownish-red spots in the colored part of the eye called Lisch nodules, benign skin tumors called neurofibromas, and larger benign tumors of nerves called plexiform neurofibromas (PN).

Here, Selumetinib (Koselugo) is approved specifically for patients who have symptomatic, inoperable plexiform neurofibromas, which are tumors involving the nerve sheaths (coating around nerve fibers) and can grow anywhere in the body, including the face, extremities, areas around the spine and deep in the body where they may affect organs. Selumetinib (Koselugo) is a kinase inhibitor, meaning it functions by blocking a key enzyme, which results in helping to stop the tumor cells from growing. With this approval, for the first time, pediatric patients now have an FDA-approved drug to treat plexiform neurofibroma.

The FDA approved Selumetinib (Koselugo) based on a clinical trial conducted by the National Cancer Institute of pediatric patients who had NF-1 and inoperable PN (defined as a PN that could not be completely removed without risk for substantial morbidity to the patient). The efficacy results were from 50 of the patients who received the recommended dose and had routine evaluations of changes in tumor size and tumor-related morbidities during the trial. Patients received Selumetinib (Koselugo) 25 mg/m2 orally twice a day until disease progression or until they experienced unacceptable adverse reactions. The clinical trial measured the overall response rate (ORR), defined as the percentage of patients with a complete response and those who experienced more than a 20% reduction in PN volume on MRI that was confirmed on a subsequent MRI within 3-6 months. The ORR was 66% and all patients had a partial response, meaning that no patients had complete disappearance of the tumor. Of these patients, 82% had a response lasting 12 months or longer. Other clinical outcomes for patients during Selumetinib (Koselugo) treatment including changes in PN-related disfigurement, symptoms and functional impairments. Although the sample sizes of patients assessed for each PN-related morbidity (such as disfigurement, pain, strength and mobility problems, airway compression, visual impairment and bladder or bowel dysfunction) were small, there appeared to be a trend of improvement in PN-related symptoms or functional deficits during treatment.

Of course, patients and treating physicians need to be concerned about common and serious side effects of Selumetinib (Koselugo) too. Common effects included vomiting, rash, abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain (i.e., pain in the body affecting bones, muscles, ligaments, tendons and nerves), fever, acneiform rashes (acne), stomatitis (inflammation of the mouth and lips), headache, paronychia (infection in the skin that surrounds a toenail or fingernail) and pruritus (itching). However, much more seriously, Selumetinib (Koselugo) can also cause effects such as heart failure (manifested as ejection fraction decrease, or when the muscle of the left ventricle of the heart is not pumping as well as normal) and ocular toxicity (acute and chronic damage to the eye) including retinal vein occlusion, retinal pigment epithelial detachment and impaired vision. Patients should have cardiac and ophthalmic assessments performed prior to initiating Selumetinib (Koselugo) and at regular intervals during treatment. Selumetinib (Koselugo) can also cause increased creatinine phosphokinase (CPK). CPK is an enzyme found in the heart, brain and skeletal muscles. When muscle tissue is damaged, CPK leaks into a person’s blood. CPK elevation in a patient receiving Selumetinib (Koselugo) should prompt an evaluation for rhabdomyolysis (breakdown of skeletal muscle due to direct or indirect muscle injury). Selumetinib (Koselugo) should be withheld, dosage reduced or dosage permanently discontinued based on the severity of adverse reactions. In addition, Selumetinib (Koselugo) contains Vitamin E, and patients are at an increased risk of bleeding if their daily intake of Vitamin E exceeds the recommended or safe limits.

Finally and very much disturbingly, based on findings from animal studies, Selumetinib (Koselugo) may cause harm to a newborn baby when administered to a pregnant woman. The FDA advises health care professionals to tell females of reproductive age, and males with female partners of reproductive potential, to use effective contraception during treatment with Selumetinib (Koselugo), and for one week after the last dose. See here the FDA-approved drug label for Selumetinib (Koselugo).

See here a short sequence on neurofibromatosis type 1 (NF-1):

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • New COVID-19 related genes—helpful and harmful—found in massive screen October 26, 2020
    Researchers at Yale University and the Broad Institute of MIT and Harvard screened hundreds of millions of cells exposed to the COVID-19 and MERS viruses and identified dozens of genes that both enable the viruses to replicate in cells and also those that seem to slam the door on the virus.
  • Genetic predisposition to increased weight is protective for breast and prostate cancer October 26, 2020
    Although a recent campaign by Cancer Research UK emphasized obesity as a risk factor for cancer on par with smoking, the scientific literature on the relationship between increased weight and cancer risk is not so clear. In a new analysis, researchers from Brunel University London found that increasing weight is causally protective for breast and […]
  • Insights into the genetic architecture of penicillin allergy October 26, 2020
    Researchers announce the first robust evidence for the role of the major histocompatibility complex gene HLA-B in penicillin allergy. To identify genetic risk factors for penicillin allergy, the international team of researchers harnessed self-reported data and the electronic health records of more than 600,000 people, as well as replicating their findings in two independent research […]
  • Breast cancer risk and disease-causing mutations in women over age 65 October 26, 2020
    Women with the onset of breast cancer over age 65 often do not qualify for genetic testing, yet little is known about the frequency of disease-causing mutations in breast cancer predisposition genes in this population. In a new study, researchers investigated the prevalence of disease-causing variants in established breast cancer predisposition genes and estimated the […]
  • Cell-free DNA provides a dynamic window into health October 26, 2020
    Short fragments of cell-free DNA (cfDNA) that circulate in blood, urine, and other biofluids can offer an information-rich window into human physiology and disease. By looking at the methylation markers of cfDNA, researchers can identify the tissue from which the DNA came. A new study used this method to monitor infectious and immune-related diseases, including […]
  • 3D printing the first ever biomimetic tongue surface October 26, 2020
    Scientists have created synthetic soft surfaces with tongue-like textures for the first time using 3D printing, opening new possibilities for testing oral processing properties of food, nutritional technologies, pharmaceutics and dry mouth therapies.
  • Surprised researchers: Number of leopards in northern China on the rise October 26, 2020
    Most of the world's leopards are endangered and generally, the number of these shy and stunning cats is decreasing. However, according to a recent study by a researcher from University of Copenhagen and colleagues from China, leopard populations in northern China are on the mend. Discover why below.
  • Powering the future: new insights into how alkali-metal doped flexible solar cells work October 26, 2020
    A group of scientists from Korea has discovered that the amount of alkali metal introduced into crystals of flexible thin-film solar cells influences the path that charge carriers take to traverse between electrodes, thereby affecting the light-to-electricity conversion efficiency of the solar cell. Given the immense application potential that such solar cells have today, this […]
  • Scientists establish NanDeSyn Database to support international cooperation on industrial microalgae October 26, 2020
    To promote resource sharing and research cooperation for the synthetic biology and molecular breeding of industrial oil-producing microalgae, an international team led by Single-Cell Center (SCC), Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences (CAS), has released the "NanDeSyn Database" (http://www.nandesyn.org).
  • A heart-breast cancer-on-a-chip monitoring system October 26, 2020
    Dual-organ system enables the measurement of cardiac toxicity arising from breast cancer chemotherapy. A collaborative team, which includes a group from the Terasaki Institute for Biomedical Innovation, has developed an organs-on-a-chip system that more widely examines the responses of breast cancer and heart tissues to therapeutic breast cancer drugs.
Top